UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | U | V | W
Number of items: 167.

A

Ah-See, MW; Makris, A; Taylor, NJ; Harrison, M; Ostler, PJ; Richman, PI; Stirling, JJ; (2004) Changes in dynamic contrast-enhanced MRI as an early predictor of response to neoadjuvant chemotherapy in primary breast cancer. British Journal of Cancer , 91 S22-S22.

Ah-See, MW; Padhani, AR; Taylor, NJ; Daley, FM; Bentzen, SM; Burcombe, RJ; Harrison, M; (2004) Tumour microvasculature, assessment by dynamic contrast- enhanced MRI fails to correlate with VEGF expression in breast cancer biopsies. British Journal of Cancer , 91 S16-S16.

Akbar, AN; Beverley, PCL; Salmon, M; (2004) Opinion - Will telomere erosion lead to a loss of T-cell memory? NAT REV IMMUNOL , 4 (9) 737 - 743. 10.1038/nri1440.

Ali, K; Bilancio, A; Thomas, M; Pearce, W; Gilfillan, AM; Tkaczyk, C; Kuehn, N; (2004) Essential role for the p110 delta phosphoinositide 3-kinase in the allergic response. NATURE , 431 (7011) pp. 1007-1011. 10.1038/nature02991.

Ali, K; Bilancio, A; Thomas, M; Pearce, W; Gilfillan, AM; Tkaczyk, C; Kuehn, N; (2004) Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature , 431 (7011) pp. 1007-1011. 10.1038/nature02991.

Alley, MC; Hollingshead, MG; Pacula-Cox, CM; Wand, WR; Hartley, JA; Howard, PW; Gregson, SJ; (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations. CANCER RES , 64 (18) 6700 - 6706.

André, T; Boni, C; Mounedji-Boudiaf, L; Navarro, M; Tabernero, J; Hickish, T; Topham, C; (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med , 350 (23) pp. 2343-2351. 10.1056/NEJMoa032709. Green open access
file

Ansari, J; Nagabhushan, N; Syed, R; Bomanji, J; Bacon, CM; Lee, SM; (2004) Small cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: Case report and literature review. CLINICAL ONCOLOGY , 16 (1) pp. 71-76. 10.1016/j.clon.2003.09.008.

Arkenau, HT; Porschen, R; (2004) Adjuvant chemotherapy in curative resected colon carcinoma. Verdauungskrankheiten , 22 (4) pp. 208-215.

Arkenau, HT; Porschen, R; (2004) Adjuvante Therapie des kolorektalen Karzinoms. Verdauungskrankheiten pp. 208-215.

B

BBC, NO; (2004) Drug boosts lung cancer survival. UNSPECIFIED

BBC, NORCR; (2004) 'They just didn't know what it would do'. UNSPECIFIED

BBC News at Ten BBC news correspondent, AM; (2004) Passive smoking is a public health hazard. UNSPECIFIED

BBC News at Ten BBC news correspondent, AM; (2004) Smart drug for lung cancer tested. UNSPECIFIED

Bagshawe, KD; Sharma, SK; Begent, RHJ; (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. EXPERT OPIN BIOL TH , 4 (11) 1777 - 1789. 10.1517/14712598.4.11.1777.

Baraldi, PG; Beria, I; Cozzi, P; Geroni, C; Espinosa, A; Gallo, MA; Entrena, A; (2004) Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studies. BIOORGAN MED CHEM , 12 (14) 3911 - 3921. 10.1016/j.bmc.2004.04.045.

Barber, L.J.; (2004) The Saccharomyces cerevisiae Snm1 gene and repair of anticancer drug-induced DNA interstrand cross-links. Doctoral thesis, University of London. Green open access
file

Bentzen, SM; Bernier, J; Khalil, AA; Saunders, MI; Horiot, JC; Van den Bogaert, W; Cummings, BJ; (2004) Estimatet effect of patient non-compliance to dose-time constraints in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Strahlentherapie und Onkologie , 180 p. 98.

Birtle, AJ; Newby, JC; Harland, SJ; (2004) Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. British Journal of Cancer , 91 (8) pp. 1472-1476.

Bouscary, D; Bardet, V; Sujobert, P; Cornillet-Lefebvre, P; Hayflick, JS; Prie, N; Verdier, F; (2004) Blockade of p110delta isoform activity of phosphoinositide 3-kinase inhibits blast cell proliferation in acute myeloblastic leukemia. In: (Proceedings) 46th Annual Meeting of the American-Society-of-Hematology. (pp. 691A-691A). AMER SOC HEMATOLOGY

Bower, M; Powles, T; Newsom-Davis, T; Thirlwell, C; Stebbing, J; Mandalia, S; Nelson, M; (2004) HIV-associated anal cancer - Has highly active antiretroviral therapy reduced the incidence or improved the outcome? JAIDS-J ACQ IMM DEF , 37 (5) 1563 - 1565.

Bower, M; Stebbing, J; Thirlwell, C; Newsom-Davis, T; Waterston, A; Mandalia, S; Gazzard, B; (2004) Anti-retroviral treatment regimens and immune parameters in the prevention of systemic HIV-related non-Hodgkin's lymphoma. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 105S - 105S). AMER SOC CLINICAL ONCOLOGY

Bower, M; Stebbing, J; Thirlwell, C; Newsom-Davis, T; Waterston, A; Mandalia, S; Gazzard, B; (2004) Anti-retroviral treatment regimens and immune parameters in the prevention of systemic HIV-related non-Hodgkin's lymphoma. J Clin Oncol , 22 (14_suppl) 1034-.

Bownes, P; Hoskin, PJ; Ostler, PJ; Lowe, GJ; Bryant, L; (2004) Quality assurance for fractionated high dose rate afterloading brachytherapy as monotherapy for prostate cancer. Radiotherapy and Oncology , 71 241-.

Burroughs, A; Hochhauser, D; Meyer, T; (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. LANCET ONCOL , 5 (7) 409 - 418.

Burroughs, A; Hochhauser, D; Meyer, T; (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol , 5 (7) pp. 409-418. 10.1016/S1470-2045(04)01508-6.

C

Calabrese, CR; Almassy, R; Barton, S; Batey, MA; Calvert, AH; Canan-Koch, S; Durkacz, BW; (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J NATL CANCER I , 96 (1) 56 - 67. 10.1093/jnci/djh005.

Calvert, AH; (2004) Biochemical pharmacology of pemetrexed. Oncology (Williston Park) , 18 (13 Suppl) pp. 13-17.

Campbell, M; Allen, WE; Sawyer, C; Vanhaesebroeck, B; Trimble, ER; (2004) Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res , 95 (4) pp. 380-388. 10.1161/01.RES.0000138019.82184.5d.

Cansick, JC; Lennon, R; Cummins, CL; Howie, AJ; McGraw, ME; Saleem, MA; Tizard, EJ; (2004) Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative)glomerulonephritis. Nephrology Dialysis Transplantation , 19 pp. 2769-2777.

Carnell, DM; Smith, RE; Daley, FM; Barber, PR; Hoskin, PJ; Wilson, GD; Murray, GI; (2004) Target validation of cytochrome P450CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. International Journal of Radiation Oncology Biology Physics , 58 (2) pp. 500-509.

Channel, 4IMF; (2004) Happy Birthday Thalidomide. UNSPECIFIED

Chester, JD; Hall, GD; Forster, M; Protheroe, AS; (2004) Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. Cancer Treat Rev , 30 (4) pp. 343-358. 10.1016/j.ctrv.2003.12.005.

Chester, K; Pedley, B; Tolner, B; Violet, J; Mayer, A; Sharma, S; Boxer, G; (2004) Engineering antibodies for clinical applications in cancer. Tumor Biology , 25 (1-2) pp. 91-98.

Chester, K; Pedley, B; Tolner, B; Violet, J; Mayer, A; Sharma, S; Boxer, G; (2004) Engineering antibodies for clinical applications in cancer. TUMOR BIOL , 25 (1-2) 91 - 98. 10.1159/000077727.

Chew, SK; Akdemir, F; Chen, P; Lu, W-J; Mills, K; Daish, T; Kumar, S; (2004) The apical caspase dronc governs programmed and unprogrammed cell death in Drosophila. Dev Cell , 7 (6) pp. 897-907. 10.1016/j.devcel.2004.09.016.

Chow, E; Thirlwell, C; Macrae, F; Lipton, L; (2004) Colorectal cancer and inherited mutations in base-excision repair. LANCET ONCOL , 5 (10) 600 - 606.

Chowdhury, S; Chester, KA; Bridgewater, J; Collins, MK; Martin, F; (2004) Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. MOL THER , 9 (1) 85 - 92. 10.1016/j.ymthe.2003.10.004.

Clamp, A; Adams, M; Atkinson, R; Boven, E; Calvert, AH; Cervantes, A; Ganesan, T; (2004) A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-895 1f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. GYNECOL ONCOL , 95 (1) 114 - 119. 10.1016/j.ygyno.2004.06.047.

Clingen, PH; Wu, J; Prise, KM; Hartley, JA; (2004) H2AX nuclear foci are induced in human cells after treatment with DNA interstrand crosslinking chemotherapeutics. BRITISH JOURNAL OF CANCER , 91 S48 - S48.

Curtin, NJ; Barlow, HC; Bowman, KJ; Calvert, AH; Davison, R; Golding, BT; Huang, B; (2004) Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha(1)-acid glycoprotein. J MED CHEM , 47 (20) 4905 - 4922. 10.1021/jm040772w.

D

Dearling, JLJ; Flynn, AA; Sutcliffe-Goulden, J; Petrie, IA; Boden, R; Green, AJ; Boxer, GM; (2004) Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J NUCL MED , 45 (1) 101 - 107.

Deloukas, P; Earthrowl, ME; Grafham, DV; Rubenfield, M; French, L; Steward, CA; Sims, SK; (2004) The DNA sequence and comparative analysis of human chromosome 10. NATURE , 429 (6990) 375 - 381. 10.1038/nature02462.

Dumez, H; Van Oosterom, AT; Rothermel, JD; Mull, R; Calvert, AH; (2004) Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer. J Clin Oncol , 22 (14_suppl) 2093-.

Dumez, H; Van Oosterom, AT; Rothermel, JD; Mull, R; Calvert, AH; (2004) Phase Ib/Il dose-escalation trial evaluating the safety and tolerability of EP0906 plus capecitabine in patients with advanced cancer. Journal of Clinical Oncology , 22 (14) 2093-.

Dunham, A; Matthews, LH; Burton, J; Ashurst, JL; Howe, KL; Ashcroft, KJ; Beare, DM; (2004) The DNA sequence and analysis of human chromosome 13. NATURE , 428 (6982) 522 - 528. 10.1038/nature02379.

E

Eardley, KS; Ferreriera, MAS; Howie, AJ; Gosling, P; Lipkin, GW; (2004) Urinary albumin excretion: a predictor of glomerular findings in microscopic haematuria. QJM , 97 pp. 297-301.

F

Feingold, EA; Good, PJ; Guyer, MS; Kamholz, S; Liefer, L; Wetterstrand, K; Collins, FS; (2004) The ENCODE (ENCyclopedia of DNA elements) Project. SCIENCE , 306 (5296) 636 - 640. 10.1126/science.1105136.

Ffolkes, LV; Freeman, A; Harland, SJ; Parkinson, MC; (2004) Are there diagnostic problems with testis tumours? JOURNAL OF PATHOLOGY , 204 35A - 35A.

Flores, L; Henry, J; Bailey, S; Tahberhai, Z; Harris, D; Buchmueller, K; Nguyen, B; (2004) JH-37, a hairpin polyamide, inhibits the binding of nuclear factor-Y to inverted CCAAT boxes in the human topoisomerase II alpha promoter. A biochemical and biophysical study. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. (pp. U26 - U27). AMER CHEMICAL SOC

Forster, MD; Madhusudan, S; Muthuramalingam, SR; Braybrooke, JP; Wilner, S; Kaur, K; Han, C; (2004) A phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor alpha Inhibitor in Patients with Metastatic Breast Cancer. Clin Cancer Res. , 10 (19) pp. 6528-6534.

Foster, C; Evans, DGR; Eeles, R; Eccles, D; Ashley, S; Brooks, L; Cole, T; (2004) Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: Attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genetic Testing , 8 (1) pp. 23-29.

Francis, RJ; Mather, SJ; Chester, K; Sharma, SK; Bhatia, J; Pedley, RB; Waibel, R; (2004) Radiolabelling of glycosylated MFE-23 :: CPG2 fusion protein (MFECP1) with Tc-99m for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). EUR J NUCL MED MOL I , 31 (8) 1090 - 1096. 10.1007/s00259-004-1474-4.

Friedmann, B; Caplin, M; Hartley, JA; Hochhauser, D; (2004) Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). CLIN CANCER RES , 10 (19) 6476 - 6486.

G

Gasco, M; Sullivan, A; Smith, P; Farrell, P; Numico, G; Colantonio, I; Merlano, M; (2004) Transcriptional silencing of Fanconi anaemia genes and clinical outcome in head and neck cancer. J Clin Oncol , 22 (14_suppl) 9546-.

Geary, J; Hodgson, SV; Homfray, T; Mackay, J; Izatt, L; Dorkins, H; Thomas, H; (2004) HNPCC - Where does the buck stop? Journal of Medical Genetics , 41 S36-S36.

Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A; (2004) Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation. ONCOGENE , 23 (34) 5864 - 5870. 10.1038/sj.onc.1207711.

Giampieri, S; Storey, A; (2004) Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from humanpapillomaviruses types 5 and 18. BRIT J CANCER , 90 (11) 2203 - 2209. 10.1038/sj.bjc.6601829.

Graff, CP; Chester, K; Begent, R; Wittrup, KD; (2004) Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. PROTEIN ENG DES SEL , 17 (4) 293 - 304. 10.1093/protein/gzh038.

Gregson, SJ; Howard, PW; Gullick, DR; Hamaguchi, A; Corcoran, KE; Brooks, NA; Hartley, JA; (2004) Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8 ' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. J MED CHEM , 47 (5) 1161 - 1174. 10.1021/jm0308971.

H

Hallowell, N; Mackay, J; Richards, M; Gore, M; Jacobs, I; (2004) High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: A descriptive study. Genetic Testing , 8 (2) pp. 148-156.

Harney, J; Shah, N; Short, S; Daley, F; Groom, N; Wilson, GD; Joiner, MC; (2004) The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiotherapy and Oncology , 70 (3) pp. 319-329. 10.1016/j.radonc.2004.01.015.

Harney, J; Short, S; Shah, N; Joiner, M; Saunders, MI; (2004) Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics , 59 (4) pp. 1190-1195. 10.1016/j.ijrobp.2003.12.029.

Hartley, JA; (2004) Assessing individual responses to anti-cancer therapy using the comet assay. Mutagenesis , 19 (6) 15-.

Hartley, JA; (2004) Assessing individual responses to anti-cancer therapy using the comet assay. MUTAGENESIS , 19 (6) 504 - 504.

Hartley, JA; Spanswick, VJ; Brooks, N; Clingen, PH; McHugh, PJ; Hochhauser, D; Pedley, RB; (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. CANCER RES , 64 (18) 6693 - 6699.

Hartley, JA; Spanswick, VJ; Brooks, N; Clingen, PH; McHugh, PJ; Hochhauser, D; Pedley, RB; (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res , 64 (18) pp. 6693-6699. 10.1158/0008-5472.CAN-03-2941.

Helena Selby, BBCWSABBCR4; (2004) BBC World Service Health Matters Programme on Lung Cancer. UNSPECIFIED

Henry, JA; Le, NM; Nguyen, B; Howard, CM; Bailey, SL; Horick, SM; Buchmueller, KL; (2004) Targeting the inverted CCAAT box 2 in the topoisomerase II alpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: Design, synthesis, molecular biology, and biophysical studies. BIOCHEMISTRY-US , 43 (38) 12249 - 12257. 10.1021/bi048785z.

Hoskin, PJ; (2004) The RIB trial. Clinical Oncology , 16 (7) pp. 445-446.

Hoskin, PJ; (2004) Should all breast cancer patients with symptomatic bone metastasis be treated with bisphosphonates? The case against. Clinical Oncology , 16 (2) pp. 112-114.

Hoskin, PJ; Decanha, SM; P, G-J; R, ; (2004) High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Radiotherapy and Oncology , 73 pp. 195-198.

Hoskin, PJ; Sibtain, A; Daley, FM; Saunders, MI; Wilson, GD; (2004) The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiotherapy and Oncology , 72 (2) pp. 159-168.

Howie, AJ; (2004) Defining the role of pathology services in the diagnosis and staging of renal cell carcinoma. In: Aitchison, M and Oliver, RTD and Miles, A, (eds.) The Effective Management of Renal Cell Carcinoma. (pp. 49-53). Aesculapius Medical Press: London.

Howie, AJ; Adu, D; (2004) Different meanings of 'glomerular tip lesion'. Kidney International , 66 1716-.

Howie, AJ; Ferreira, MAS; Lipkin, GW; Adu, D; (2004) Measurement of chronic damage in the donor kidney and graft survival. Transplantation , 77 pp. 1058-1065. 10.1097/01.TP.0000120177.44144.FF.

Huhalov, A; Chester, KA; (2004) Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging , 48 (4) pp. 279-288.

Huhalov, A; Graff, C; Wittrup, KD; Tolner, B; Pedley, RB; Vervecken, W; Contreras, R; (2004) HSAbodies: A new class of engineered antibody-based molecules for targeting cancer. BRITISH JOURNAL OF CANCER , 91 S63 - S63.

Huhalov, A; Spencer, DIR; Chester, KA; (2004) A strategy for characterizing antibody/antigen interactions using proteinchip arrays. In: Conn, PM, (ed.) Handbook of proteomic methods. (pp. 117-128). Humana Press: New Jersey.

Huhalov, A.; (2004) Design and cancer-targeting potential of antibody-based molecules directed against carcinoembryonic antigen. Doctoral thesis, University of London. Green open access
file

Humphray, SJ; Oliver, K; Hunt, AR; Plumb, RW; Loveland, JE; Howe, KL; Andrews, TD; (2004) DNA sequence and analysis of human chromosome 9. NATURE , 429 (6990) 369 - 374. 10.1038/nature02465.

J

Jia, L; Spanswick, VJ; Reid, JM; Kuffel, M; Buhrow, SA; Ames, MM; Hartley, JA; (2004) Use of the comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to lymphocytes. Proceedings of the American Association for Cancer Research , 45 1969-.

K

Kakkar, AK; Bundred, N; Carpenter, R; Makris, A; Merriman, H; Walker, ID; (2004) Venous thromboembolism in cancer patients. Guidelines. EGUIDELINES , 23 pp. 311-314.

Kalra, D; Singleton, P; Ingram, D; Milan, J; MacKay, J; Detmer, D; Rector, A; (2004) Security and confidentiality approach for the Clinical E-ScienceFramework (CLEF). In: (Proceedings) Health Grid 2004. : Clermont-Ferrand, France.

Kemp, Z; Thirlwell, C; Sieber, O; Silver, A; Tomlinson, I; (2004) An update on the genetics of colorectal cancer. HUM MOL GENET , 13 R177 - R185. 10.1093/hmg/ddh247.

Kiakos, K; Hartley, JA; Price, C; Lingerfelt, B; Handl, H; Lee, M; (2004) Design, synthesis and DNA alkylation specificity of novel achiral seco-CI-polyamide hairpin conjugates. Proceedings of the American Association for Cancer Research , 45 3091-.

Kiakos, K; Mchugh, PJ; Hartley, JA; Sato, K; Summerville, K; C, L; M, ; (2004) Design, synthesis and biological evaluation of AS-I-145, a novel achiral amino seco-CBI. Proceedings of the American Association for Cancer Research , 45 3998-.

Kim, JB; O'Hare, MJ; Stein, R; (2004) Models of breast cancer: is merging human and animal models the future? Breast Cancer Res , 6 (1) pp. 22-30. 10.1186/bcr645.

Kim, JB; Stein, R; O'Hare, MJ; (2004) Three-dimensional in vitro tissue culture models of breast cancer-- a review. Breast Cancer Res Treat , 85 (3) pp. 281-291. 10.1023/B:BREA.0000025418.88785.2b.

Kristeleit, RS; Stimson, L; Workman, P; Aherne, G; (2004) Histone modification enzymes: novel targets for cancer drugs. Expert Opinion on Emerging Drugs , 9 (1)

Kupchinsky, S; Centioni, S; Howard, T; Trzupek, J; Roller, S; Carnahan, V; Townes, H; (2004) A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties. BIOORGAN MED CHEM , 12 (23) 6221 - 6236.

Kupchinsky, S; Centioni, S; Howard, T; Trzupek, J; Roller, S; Carnahan, V; Townes, H; (2004) A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties. Bioorganic and Medicinal Chemistry , 12 (23) pp. 6221-6236.

L

Lacy, ER; Nguyen, B; Le, M; Cox, KK; O'Hare, C; Hartley, JA; Lee, M; (2004) Energetic basis for selective recognition of T center dot G mismatched base pairs in DNA by imidazole-rich polyamides. NUCLEIC ACIDS RES , 32 (6) 2000 - 2007. 10.1093/nar/gkh515. Gold open access

Landreau, CAS; LePla, RC; Shipman, M; Slawin, AMZ; Hartley, JA; (2004) Delineating noncovalent interactions between the azinomycins and double-stranded DNA: Importance of the naphthalene substitution pattern on interstrand cross-linking efficiency. ORG LETT , 6 (20) 3505 - 3507. 10.1021/ol048653y.

Le Pla, RC; Landreau, CAS; Shipman, M; Slawin, AMZ; Hartley, JA; (2004) The role of the naphthoate moiety and its substituents upon the efficiency of DNA interstrand cross-linking by the azinomycins. Mutagenesis , 19 (6) 51-.

Le Pla, RC; Landreau, CAS; Shipman, M; Slawin, AMZ; Hartley, JA; (2004) The role of the naphthoate moiety and its substituents upon the efficiency of DNA interstrand cross-linking by the azinomycins. MUTAGENESIS , 19 (6) 516 - 516.

Litchfield, TM; Gilchrist, S; Sunderland, R; Folkard, M; Short, S; Prise, K; (2004) A three dimensional tissue culture model for microbeam studies. In: (pp. P 462.4-).

Liu, WM; Strauss, SJ; Chaplin, T; Shahin, S; Propper, DJ; Young, BD; Joel, SP; (2004) s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J , 5 (3) 247-54-247-54.

M

Makris, A; (2004) Critical commentary of: HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Women's Oncology Review , 4 pp. 277-278.

Makris, A; (2004) Critical commentary of: Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. Women's Oncology Review , 4 pp. 213-214.

Makris, A; Glynne-Jones, R; Sebag-Montefiore, D; Samuel, L; Myint, S; Levine, E; Martin, A; (2004) Compliance to chemotherapy with oxaliplatin and 5fluorouracil in patients with advanced rectal cancer who rave received prior high-dose pelvic radiotherapy. British Journal of Cancer , 91 S34-S34.

Mayer, A; Francis, R; Sharma, SK; Sully, C; Parker, S; Tolner, B; Griffin, N; (2004) A phase I/II trial of antibody directed enzyme prodrug therapy (ADEPT) with MFECP1 and ZD2767P. British Journal of Cancer , 91 S8-S8.

Mayer, A; Francis, R; Sharma, SK; Sully, C; Parker, S; Tolner, B; Griffin, N; (2004) A phase I/II trial of antibody directed enzyme prodrug therapy (ADEPT) with MFECP1 and ZD2767P. In: BRITISH JOURNAL OF CANCER. (pp. S8 - S8). NATURE PUBLISHING GROUP

Mayer, A; Sharma, SK; Tolner, B; Minton, NP; Purdy, D; Amlot, P; Tharakan, G; (2004) Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 90 (12) 2402 - 2410. 10.1038/sj.bjc.6601888.

Mayer, A; Sharma, SK; Tolner, B; Minton, NP; Purdy, D; Amlot, P; Tharakan, G; (2004) Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer , 90 (12) pp. 2402-2410. 10.1038/sj.bjc.6601888.

McGurk, CJ; Cummings, M; Hartley, JA; Masters, JR; (2004) Translational regulation of ERCC1 in human cancer cell lines. Proceedings of the American Association for Cancer Research , 45 2631-.

McMeish, I; Kanfer, EJ; Haynes, R; Giles, C; Harland, SJ; Driver, D; Rustin, GJS; (2004) Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. British Journal of Cancer , 90 (6) pp. 1169-1175.

McTiernan, A; Whelan, JS; (2004) A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma , 8 (2-3) pp. 71-76. 10.1080/13577140410001711764. Gold open access

Mchugh, PJ; Hartley, JA; (2004) Repair of DNA interstrand crosslinks Produced by Cancer Chemotherapeutic Drugs. In: Panasci, LC and Alaoui-Jamali, MA, (eds.) DNA Repair in Cancer Therapy. (pp. 31-49). Humana Press: Totowa. NJ.

Medzihradszky, KF; Spencer, DIR; Sharma, SK; Bhatia, J; Pedley, RB; Read, DA; Begent, RHJ; (2004) Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. GLYCOBIOLOGY , 14 (1) 27 - 37. 10.1093/glycob/cwh001.

Moroncini, G; Kanu, N; Solforosi, L; Abalos, G; Telling, GC; Head, M; Ironside, J; (2004) Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. P NATL ACAD SCI USA , 101 (28) 10404 - 10409. 10.1073/pnas.0403522101.

N

Newsom-Davis, T; Bower, M; Wildfire, A; Thirlwell, C; Nelson, M; Gazzard, B; Stebbing, J; (2004) Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. LEUKEMIA LYMPHOMA , 45 (9) 1939 - 1941. 10.1080/10428190410001693533.

Novak-Hofer, I; Waibel, R; Zimmermann, K; Schibli, R; Grünberg, ; J, ; Chester, ; (2004) Radiometal labeling of antibodies and antibody fragments for imaging and therapy. In: Methods Mol Biol. (pp. 481-494). Humana Press

O

O'Donnell, A; Judson, I; Dowsett, M; Raynaud, F; Dearnaley, D; Mason, M; Harland, S; (2004) Hormonal impact of the 17 alpha-hydroxylase/C-17,C-20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer , 90 (12) pp. 2317-2325.

Okkenhaug, K; Bilancio, A; Emery, JL; Vanhaesebroeck, B; (2004) Phosphoinositide 3-kinase in T cell activation and survival. BIOCHEMICAL SOCIETY TRANSACTIONS , 32 pp. 332-335. 10.1042/BST0320332.

Okkenhaug, K; Bilancio, A; Emery, JL; Vanhaesebroeck, B; (2004) Phosphoinositide 3-kinase in T cell activation and survival. Circulation Research , 95 (4) pp. 380-388.

P

Papazisis, KT; Habeshaw, T; Miles, DW; Herceptin-EAP Study Group, ; (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. Int J Clin Pract , 58 (6) pp. 581-586.

Parker, LL; Lacy, SM; Farrugia, LJ; Evans, C; Robins, DJ; O'Hare, CC; Hartley, JA; (2004) A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J MED CHEM , 47 (23) 5683 - 5689. 10.1021/jm0449866w.

Pedley, RB; Sharma, SK; Hawkins, RE; Chester, KA; (2004) Antibody-directed enzyme-prodrug therapy. In: UNSPECIFIED (pp. 491-514).

Pedley, RB; Sharma, SK; Hawkins, RE; Chester, KA; (2004) Antibody-directed enzyme-prodrug therapy. In: UNSPECIFIED (pp. 491-514).

Peltenburg, LTC; de Bruin, EC; Meersma, D; Wilting, S; Jürgensmeier, JM; Schrier, PI; (2004) c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers. Melanoma Res , 14 (1) pp. 3-12.

Pereira, JJ; Meyer, T; Docherty, SE; Reid, HH; Marshall, J; Thompson, EW; Rossjohn, J; (2004) Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res , 64 (3) pp. 977-984.

Pors, K; Paniwnyk, Z; Ruparelia, KC; Teesdale-Spittle, PH; Hartley, JA; Kelland, LR; Patterson, LH; (2004) Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor. J MED CHEM , 47 (7) 1856 - 1859. 10.1021/jm031070u.

R

Reed, JR; Vukmanovic-Stejic, M; Fletcher, JM; Soares, MVD; Cook, JE; Orteu, CH; Jackson, SE; (2004) Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J EXP MED , 199 (10) 1433 - 1443. 10.1084/jem.20040178.

Reif, K; Okkenhaug, K; Sasaki, T; Penninger, JM; Vanhaesebroeck, B; Cyster, JG; (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol , 173 (4) pp. 2236-2240.

S

Sartor, O; Reid, RH; Hoskin, PJ; Quick, DP; Ell, PJ; Coleman, RE; Kotler, JA; (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. UROLOGY , 63 (5) 940 - 945. 10.1016/j.urology.2004.01.034.

Saunders, MI; Rojas, AM; (2004) Management of cancer of the head and neck--a cocktail with your PORT? N Engl J Med , 350 (19) pp. 1997-1999. 10.1056/NEJMe048038.

Short, S; (2004) UNSPECIFIED In: (Proceedings) ESTRO 23, Amsterdam.

Short, SC; Suovuori, A; Cook, G; Vivian, G; Harmer, C; (2004) A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clinical Oncology , 16 (8) pp. 569-574.

Short, SM; Makris, A; Jones, RG; Novell, R; Harrison, M; (2004) Low dose continuous hyperfractionated accelerated radiation therapy (CHART) as preoperative treatment for rectal carcinoma. British Journal of Cancer , 91 S38-S38.

Sibtain, A; Saunders, MI; Bentzen, SM; Hoskin, PJ; (2004) Pre-treatment haemoglobin concentration in accelerated and conventional radiotherapy for non-small cell lung carcinoma. Clinical Oncology , 16 (1) pp. 58-62.

Sieber, OM; Howarth, KM; Thirlwell, C; Rowan, A; Mandir, N; Goodlad, RA; Gilkar, A; (2004) Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (Apc(Min/+)) mice. CANCER RES , 64 (24) 8876 - 8881.

Sky, NRJJ; (2004) Cost issues behind government health reforms. UNSPECIFIED

Soares, MVD; Plunkett, FJ; Verbeke, CS; Cook, JE; Faint, JM; Belaramani, LL; Fletcher, JM; (2004) Integration of apoptosis and telomere erosion in virus-specific CD8(+) T cells from blood and tonsils during primary infection. BLOOD , 103 (1) 162 - 167. 10.1182/blood-2003-06-1791.

Stewart, G; Lee, SM; (2004) Poor performance status patients and the TOPICAL Trial. Lung Cancer in Practice , 1 (3) pp. 1-3.

Stewart, M; Daniell, K; Madsen, E; Le, M; Handl, H; Brooks, N; Kiakos, K; (2004) Novel class of duocarmycin analogs: Design, synthesis and biological evaluation of achiral analogs of duocarmycin SA. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. (pp. U29 - U29). AMER CHEMICAL SOC

Stewart, M; Daniell, K; Madsen, E; Le, M; Handl, H; Brooks, N; Kiakos, K; (2004) Novel class of duocarmycin analogs: Design, synthesis and biological evaluation of achiral analogs of duocarmycin SA. In: (pp. U29-U29).

Strauss, SJ; McTiernan, A; Whelan, JS; (2004) Late relapse of osteosarcoma: Implications for follow-up and screening. Pediatric Blood and Cancer , 43 (6) pp. 692-697. 10.1002/pbc.20154.

Strauss, SJ; McTiernan, A; Whelan, JS; (2004) Late relapse of osteosarcoma: Implications for follow-up and screening. PEDIATR BLOOD CANCER , 43 (6) 692 - 697. 10.1002/pbc.20154.

Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene , 23 (19) pp. 3328-3337. 10.1038/sj.onc.1207428.

Swanton, C; (2004) Cell-cycle targeted therapies. Lancet Oncol , 5 (1) pp. 27-36.

Swanton, C; Johnston, S; (2004) New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France. IDrugs , 7 (4) pp. 306-311.

Swanton, C; Nicke, B; Downward, J; (2004) RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy? Lancet Oncol , 5 (11) pp. 653-654. 10.1016/S1470-2045(04)01604-3.

T

T M Litchfield, G; S, S; R, F; M, S; S, P; K, ; (2004) UNSPECIFIED In: (Proceedings) Society for Neuroscience 34th Annual Meeting.

Taghian, A; Jagsi, R; Makris, A; Goldberg, S; Ceilley, E; Grignon, L; Powell, S; (2004) Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: Practice is culture driven rather than evidence based. International Journal of Radiation Oncology Biology Physics , 60 (3) pp. 706-714.

Taylor, CM; Chua, C; Howie, AJ; Risdon, RA; (2004) Clinico-pathological findings in haemolytic uraemic syndrome not associated with diarrhoea. Pediatric Nephrology , 19 pp. 419-425.

Thomas, R; Godward, S; Makris, A; Bloomfield, D; Moody, AM; Williams, M; (2004) Giving patients a choice improves quality of life: A multi- centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clinical Oncology , 16 (7) pp. 485-491.

Tikhe, JG; Webber, SE; Hostomsky, Z; Maegley, KA; Ekkers, A; Li, JK; Yu, XH; (2004) Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J MED CHEM , 47 (22) 5467 - 5481. 10.1021/jm030513r.

Twelves, C; Gokul, S; Jones, RH; Boddy, A; Macham, M; Fishwick, K; Wheaton, J; (2004) Phase I study to evaluate the safety, tolerability and pharmacokinetics of OSI-211 (Liposomal Lurtotecan) in combination with Carboplatin. ANN ONCOL , 15 105 - 105.

U

Urbaniak, MD; Bingham, JP; Hartley, JA; Woolfson, DN; Caddick, S; (2004) Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin. J MED CHEM , 47 (19) 4710 - 4715. 10.1021/jm040790d.

Urbaniak, MD; Bingham, JP; Hartley, JA; Woolfson, DN; Caddick, S; (2004) Improved Stability of Nitrogen-Mustard Derivatives Using apo-Neocarzinostatin. Journal of Medicinal Chemistry , 47 pp. 4710-4715.

V

Van Zuylen, L; Bridgewater, J; Sparreboom, A; Eskens, FALM; De Bruijn, P; Sklenar, I; Planting, AST; (2004) Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/Leucovorin in Metastatic Colorectal Cancer. Clinical Cancer Research , 10 (6) pp. 1949-1955. 10.1158/1078-0432.CCR-02-0995.

Vanhaesebroeck, B; Rohn, JL; Waterfield, MD; (2004) Gene targeting: Attention to detail. CELL , 118 (3) pp. 274-276. 10.1016/j.cell.2004.07.018.

Vanhaesebroeck, B; Rohn, JL; Waterfield, MD; (2004) Gene targeting: attention to detail. Cell , 118 (3) pp. 375-387.

Vassileva, V; Millar, A; Briollais, L; Chapman, W; Bapat, B; (2004) Apoptotic and growth regulatory genes as mutational targets in mismatch repair deficient endometrioid adenocarcinomas of young patients. ONCOLOGY REPORTS , 11 (4) pp. 931-937.

Vassileva, VT; (2004) Release profile characterization of a novel Implantable paclitaxel loaded lipid polymer system in CD-1 mice. In: (Proceedings) American Association of Pharmaceutical Scientists Annual Meeting and Exposition.

Venables, K; Miles, EA; Aird, EGA; Hoskin, PJ; (2004) The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiotherapy and Oncology , 71 (3) pp. 303-310.

Venables, K; Miles, EA; Deighton, A; Aird, EGA; Hoskin, PJ; (2004) Irradiation of the heart during tangential breast treatment: a study within the START trial. British Journal of Radiology , 77 (914) pp. 137-142.

van Zuylen, L; Bridgewater, J; Sparreboom, A; Eskens, FALM; de Bruijn, P; Sklenar, I; Planting, AST; (2004) Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. CLIN CANCER RES , 10 (6) 1949 - 1955.

W

Wallace, E; Hinds, A; Campbell, H; Mackay, J; Cetnarskyj, R; Porteous, ME; (2004) A cross-sectional survey to estimate the prevalence of family history of colorectal, breast and ovarian cancer in a Scottish general practice population. British Journal of Cancer , 91 (8) pp. 1575-1579.

Waterston, A; Thirlwell, C; Newsom-Davis, T; Powles, T; Nelson, M; Gazzard, B; Bower, M; (2004) Does highly active antiretroviral therapy (HAART) affect the incidence or outcome of invasive anal cancer? In: BRITISH JOURNAL OF CANCER. (pp. S13 - S13). NATURE PUBLISHING GROUP

Watson, M; Foster, C; Eeles, R; Eccles, D; Ashley, S; Davidson, R; Mackay, J; (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer , 91 (10) pp. 1787-1794. 10.1038/sj.bjc.6602207.

Whelan, J; (2004) Late Effects of Childhood Cancer. Lancet Oncology

Whelan, JS; McTiernan, A; (2004) for the London Bone and Soft Tissue Tumour Service. A prospective study of pre-operative chemotherapy with single agent ifosfamide for malignant fibrous histiocytoma of bone. Sarcoma , 8 pp. 77-82. Gold open access

Whelan, JS; McTiernan, A; Kakouri, E; Kilby, A; London Bone and Soft Tissue Tumour, ; (2004) Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. PEDIATR BLOOD CANCER , 43 (3) 237 - 242. 10.1002/pbc.20107.

Whelan, JS; McTiernan, AM; Strauss, SJ; (2004) Single centre experience of a new intensive induction therapy for Ewing’s family of tumours using Holoxan in the VIDE regimen. Final results and conclusions. In:

Whelan, JS; Morland, B; (2004) Bone Tumours. In: Pinkerton, CR and Plowman, P, (eds.) Paediatric Oncology. Clinical Practice and Controversies. : London.

This list was generated on Sun Apr 23 02:56:05 2017 BST.